News Markets Markets: World’s Leading Drug Companies Finding A Way Into...

Markets: World’s Leading Drug Companies Finding A Way Into Cannabis.

-

Advertising

THE emerging cannabis industry is moving up the agenda for the pharmaceutical industry with two significant deals announced in the last few months.

Over the years, concerns the major pharmaceutical firms are anti-cannabis have been widespread and that may well be the case with recreational cannabis – as witnessed by the 2017 Insys case in Arizona.

But when it comes to medicinal cannabis – and the opportunity to secure patents – it’s looking different.

German Pharma Moving Ahead

Earlier this month German pharma giant Stada signed a supply agreement with Canadian firm MediPharm Labs. Stada employs over 10,000 people, and with annual revenues in excess of £2bn it has a product presence in 120 countries.

Canadian firm MediPharm Labs is a global leader in pharma-grade cannabis Active Pharmaceutical Ingredients with a focus on Europe.

Under the terms of the agreement MediPharm will supply GMP-certified medical cannabis products to Stada, as well as manufacturing, logistics, and regulatory support. 

Stada will be responsible for commercialising the products, initially in Germany and then the rest of the continent, as well as marketing and medical education.

In July, a second German company Neuraxpharm, a £450m annual turnover business with 850 employees, and Israeli medical cannabis manufacturer Panaxia Global launched a collaboration to market Panaxia’s medical cannabis products in Germany.

Neuraxpharm specializes in developing treatments for the Central Nervous System such as epilepsy, Parkinson’s, psychosis and depression.

Setback For US Firm

However, the cannabis industry has not proven to be an overly successful venture for one US firm after it suffered two setbacks this year.

Nasdaq-listed Corbus Pharmaceuticals has seen its synthetic cannabis drug Lenabasum fail in two clinical trials this year, wiping 77% of its share value. 

Revenues for a successful completion of the trials had been estimated US$5bn a year.

While many leading cannabis figures, including Prof David Nutt, argue ‘big pharma’ is sitting on the cannabis sidelines as it cannot secure patents on the plant’s many compounds, evidence is mounting to the contrary.

GW Pharmaceuticals is successfully advancing with their patented cannabis drugs Sativex and Epidiolex and it looks like many more are set to follow.

In a recent interview with BusinessCann UK firm Brains Bioceuticals outlined its plans to follow a similar route and develop cannabis medicine patents.

Canadian Pharma Firms Patent Cannabis Medicine

Patent lawyers highlights how, over 100 years since amphetamine was first discovered, drug companies are still securing patent protections for novel formulations.

Research from 2018 discovered that ‘big pharma’ had already arrived in the cannabis space with seven of Canada’s top 10 cannabis patent holders being multi-national pharmaceutical companies.

These include; Ciba-Geigy AG, of Switzerland with 21 patents, Pfizer Products with 14, and Telefonaktiebolaget LM Ericsson in Sweden with 13.

UK analysts Prohibition Partners will soon be launching its Pharmaceutical Cannabis Report examining how moves to get products developed, patented and approved by groups like the US Food and Drugs Administration and the European Medicines Agency is well underway. 

It identifies over over 40 clinical trials being run by the worlds’ leading cannabis companies such as Aurora and Canopy Growth. 

“The prize for the company who gets their pharmaceutical cannabis product to market will be that significant portion of the medicinal cannabis market which will belong to medicines more closely resembling traditional, single molecule pharmaceuticals which have passed through rigorous clinical trials. 

“The success of Epidiolex in establishing nine-figure annual sales is a strong testament to this,” it says.

Peter
Peter McCusker is an experienced news and business editor, who believes it’s time to fully embrace the multiple, proven, medical benefits of the cannabis plant.

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Latest news

Markets: US Firm Swoops For UK Medical Cannabis Company, EMMAC, Alphagreen, Ananda et al…

AMERICAN firm Halo Labs has snapped up UK medicinal cannabis supplier Canmart in a share-based deal. Kent-based Canmart was one...

Walking In The Light With Carlos Santana And Prohibition Partners

MUSIC legend Carlos Santana rounded-off this year’s second Prohibition Partners Live discussing his new cannabis venture, his relationship with...

European Commission Under Increasing Pressure To Scrap Its Classification Of CBD As A Narcotic Drug Following Court Ruling

THE European Court of Justice has handed the continent’s hemp and CBD industry a major boost - now the...

Huge Result For CBD Industry With Europe’s Top Court Saying It Is Not A Narcotic

THE KanaVape ruling is in and it's a massive win for the CBD industry with the ECJ saying that...

Advertising

KanaVape’s Antonin Cohen Speaks To BusinessCann After Winning His Six-Year CBD Court Battle With Europe

A JOYFUL Antonin Cohen has spoken of his delight - and relief - after successfully winning a court battle...

KanaVape Judgement Expected Soon; Stay Tuned To BusinessCann For Running Updates From 8.30am-ish GMT

TODAY could be a significant one in the history of Europe’s CBD industry with the European Court of Justice...

Must read

Markets: US Firm Swoops For UK Medical Cannabis Company, EMMAC, Alphagreen, Ananda et al…

AMERICAN firm Halo Labs has snapped up UK medicinal...

Walking In The Light With Carlos Santana And Prohibition Partners

MUSIC legend Carlos Santana rounded-off this year’s second Prohibition...

Advertising

You might also likeRELATED
Recommended to you